Bausch Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH, and when can generic versions of BAUSCH drugs launch?
BAUSCH has one hundred and seventy-six approved drugs.
There are one hundred and twenty-one US patents protecting BAUSCH drugs.
There are seven hundred and seventy-one patent family members on BAUSCH drugs in fifty-two countries and two hundred and eight supplementary protection certificates in sixteen countries.
Summary for Bausch
International Patents: | 771 |
US Patents: | 121 |
Tradenames: | 155 |
Ingredients: | 122 |
NDAs: | 176 |
Patent Litigation for Bausch: | See patent lawsuits for Bausch |
Drugs and US Patents for Bausch
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | DOXYCYCLINE HYCLATE | doxycycline hyclate | CAPSULE, DELAYED RELEASE;ORAL | 065281-001 | Dec 21, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 8,592,450 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Bausch | CARDIZEM CD | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020062-001 | Aug 10, 1992 | AB3 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-001 | Feb 6, 2003 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | RX | Yes | Yes | 11,648,256 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Bausch | TIAZAC | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020401-006 | Oct 16, 1998 | AB4 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | RETIN-A MICRO | tretinoin | GEL;TOPICAL | 020475-002 | May 10, 2002 | 4,690,825 | ⤷ Try a Trial |
Bausch | VIRAZOLE | ribavirin | FOR SOLUTION;INHALATION | 018859-001 | Dec 31, 1985 | 4,211,771 | ⤷ Try a Trial |
Bausch | CESAMET | nabilone | CAPSULE;ORAL | 018677-001 | Dec 26, 1985 | 4,087,545 | ⤷ Try a Trial |
Bausch | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-005 | Jul 23, 2009 | 5,908,838 | ⤷ Try a Trial |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | 6,426,335 | ⤷ Try a Trial |
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | 5,476,875 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Cream | 3.75% | ➤ Subscribe | 2012-08-08 |
➤ Subscribe | Extended-release Tablets | 522 mg | ➤ Subscribe | 2009-12-24 |
➤ Subscribe | For Inhalation Solution | 6 gm/vial | ➤ Subscribe | 2014-05-22 |
➤ Subscribe | Extended-release Tablets | 420 mg | ➤ Subscribe | 2005-04-25 |
➤ Subscribe | Rectal Gel | 5 mg/mL, 4mL pre-filled syringe | ➤ Subscribe | 2008-12-08 |
➤ Subscribe | Extended-release Tablet | 55 mg and 80 mg | ➤ Subscribe | 2010-12-02 |
➤ Subscribe | Gel | 1.2%/2.5% | ➤ Subscribe | 2012-12-20 |
➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2004-09-21 |
➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
➤ Subscribe | Vaginal Gel | 0.75% | ➤ Subscribe | 2004-09-02 |
➤ Subscribe | Cream | 5% | ➤ Subscribe | 2006-10-17 |
➤ Subscribe | Topical Solution | 10% | ➤ Subscribe | 2018-06-06 |
➤ Subscribe | Cream | 0.10% | ➤ Subscribe | 2008-01-31 |
➤ Subscribe | Extended-release Tablets | 348 mg | ➤ Subscribe | 2009-09-24 |
➤ Subscribe | Cream | 2.5% | ➤ Subscribe | 2014-06-17 |
➤ Subscribe | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | ➤ Subscribe | 2005-08-30 |
➤ Subscribe | Rectal Gel | 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL | ➤ Subscribe | 2004-03-23 |
➤ Subscribe | Extended-release Tablets | 65 mg and 115 mg | ➤ Subscribe | 2009-11-19 |
➤ Subscribe | Rectal Gel | 5 mg/mL, 2mL pre-filled syringe | ➤ Subscribe | 2008-12-23 |
➤ Subscribe | Extended-release Tablet | 105 rng | ➤ Subscribe | 2010-12-28 |
➤ Subscribe | Gel | 1.2%/3.75% | ➤ Subscribe | 2015-09-30 |
➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
➤ Subscribe | Gel | 1.2%/0.025% | ➤ Subscribe | 2010-12-17 |
➤ Subscribe | Gel | 0.77% | ➤ Subscribe | 2006-05-10 |
➤ Subscribe | Lotion | 0.1% | ➤ Subscribe | 2016-08-31 |
➤ Subscribe | Extended-release Tablets | 174 mg | ➤ Subscribe | 2009-09-28 |
International Patents for Bausch Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2013130577 | ⤷ Try a Trial |
New Zealand | 708821 | ⤷ Try a Trial |
Poland | 3442480 | ⤷ Try a Trial |
Japan | 2015038101 | ⤷ Try a Trial |
Australia | 2013314370 | ⤷ Try a Trial |
Mexico | 2016002485 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0957929 | PA2006004 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131 |
0957929 | PA2006004,C0957929 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131 |
0579826 | SPC/GB02/042 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422 |
2316456 | SPC/GB17/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330 |
2712622 | 122017000006 | Germany | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504 |
0473687 | SPC/GB98/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.